Innoviva ROA 2010-2024 | INVA

Current and historical return on assets (ROA) values for Innoviva (INVA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Innoviva ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2024-03-31 $0.18B $1.27B 15.11%
2023-12-31 $0.18B $1.24B 15.38%
2023-09-30 $0.05B $1.19B 4.29%
2023-06-30 $0.23B $1.12B 19.47%
2023-03-31 $0.23B $1.13B 19.39%
2022-12-31 $0.22B $1.23B 17.90%
2022-09-30 $0.29B $1.33B 26.05%
2022-06-30 $0.10B $1.14B 9.76%
2022-03-31 $0.19B $1.11B 20.17%
2021-12-31 $0.27B $0.93B 28.73%
2021-09-30 $0.31B $0.89B 32.84%
2021-06-30 $0.27B $0.79B 27.90%
2021-03-31 $0.25B $1.09B 26.02%
2020-12-31 $0.22B $1.00B 24.96%
2020-09-30 $0.22B $0.92B 26.06%
2020-06-30 $0.23B $0.88B 29.72%
2020-03-31 $0.19B $0.79B 26.70%
2019-12-31 $0.16B $0.73B 24.00%
2019-09-30 $0.38B $0.68B 61.24%
2019-06-30 $0.38B $0.64B 74.44%
2019-03-31 $0.40B $0.59B 91.17%
2018-12-31 $0.40B $0.55B 109.85%
2018-09-30 $0.19B $0.28B 60.27%
2018-06-30 $0.17B $0.34B 48.62%
2018-03-31 $0.15B $0.28B 41.79%
2017-12-31 $0.13B $0.37B 35.22%
2017-09-30 $0.10B $0.39B 26.34%
2017-06-30 $0.09B $0.37B 24.31%
2017-03-31 $0.07B $0.39B 18.95%
2016-12-31 $0.06B $0.38B 15.57%
2016-09-30 $0.04B $0.37B 9.83%
2016-06-30 $0.02B $0.38B 4.46%
2016-03-31 $-0.01B $0.39B -1.18%
2015-12-31 $-0.02B $0.41B -4.45%
2015-09-30 $-0.04B $0.44B -8.37%
2015-06-30 $-0.06B $0.46B -11.05%
2015-03-31 $-0.11B $0.49B -20.64%
2014-12-31 $-0.17B $0.52B -29.56%
2014-09-30 $-0.20B $0.55B -33.20%
2014-06-30 $-0.23B $0.61B -35.81%
2014-03-31 $-0.20B $0.61B -31.57%
2013-12-31 $-0.17B $0.68B -26.84%
2013-09-30 $-0.15B $0.67B -27.18%
2013-06-30 $-0.14B $0.60B -28.66%
2013-03-31 $-0.14B $0.59B -32.11%
2012-12-31 $-0.02B $0.37B -5.26%
2012-09-30 $-0.02B $0.38B -7.62%
2012-06-30 $-0.02B $0.40B -6.90%
2012-03-31 $-0.01B $0.22B -3.01%
2011-12-31 $-0.12B $0.26B -40.00%
2011-09-30 $-0.10B $0.28B -31.82%
2011-06-30 $-0.09B $0.30B -30.29%
2011-03-31 $-0.08B $0.32B -30.80%
2010-12-31 $-0.08B $0.33B -32.75%
2010-09-30 $-0.09B $0.21B -39.73%
2010-06-30 $-0.09B $0.23B -41.61%
2010-03-31 $-0.09B $0.25B -43.41%
2009-12-31 $-0.09B $0.18B -43.31%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.073B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $814.944B 117.78
Novo Nordisk (NVO) Denmark $590.290B 45.36
Johnson & Johnson (JNJ) United States $372.289B 14.76
Merck (MRK) United States $318.551B 57.96
AbbVie (ABBV) United States $304.294B 15.72
AstraZeneca (AZN) United Kingdom $244.043B 21.22
Novartis AG (NVS) Switzerland $216.930B 15.08
Pfizer (PFE) United States $169.828B 21.11
Sanofi (SNY) $128.207B 12.08